drugset

drugset / Trial / NCT03489629

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629 ↗

Phase 2 Completed 37 enrolled University of North Carolina, Chapel Hill Cook Children's Medical Center · collab Indiana University · collab St. Louis Children's Hospital · collab University of Michigan · collab University of Texas Southwestern Medical Center · collab University of Washington · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.

Timeline

Start: 2018-04-03
Primary completion: 2025-09-30
Completion: 2026-01-31

Publications

Background Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH; STAR-too study team. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax. 2017 Apr;72(4):318-326. doi: 10.1136/thoraxjnl-2016-208949. Epub 2016 Nov 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Chlorhexidine gluconate	Other / unclassified	—	Oral
Subject	Minocycline	Small molecule	2 mg/kg	Oral
Subject	Minocycline	Small molecule	100 mg	Oral
Subject	Mupirocin	Small molecule	1 g	Intranasal
Subject	Sulfamethoxazole	Small molecule	40 mg/kg	Oral
Subject	Sulfamethoxazole	Small molecule	1600 mg	Oral
Subject	Trimethoprim	Small molecule	8 mg/kg	Oral
Subject	Trimethoprim	Small molecule	320 mg	Oral

Indications